A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants
Information source: Janssen Research & Development, LLC
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Participants
Intervention: TMC435 (Drug); Atorvastatin (Drug); Simvastatin (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Janssen Research & Development, LLC Official(s) and/or principal investigator(s): Janssen Research & Development, LLC Clinical Trial, Study Director, Affiliation: Janssen Research & Development, LLC
Summary
The purpose of this study is to evaluate effects of steady-state concentrations (constant
concentration of medication in the blood) of TMC435 on the single dose pharmacokinetics
(what the body does to the medication) of atorvastatin, the active metabolites ortho- and
parahydroxylated atorvastatin, simvastatin and the active metabolite simvastatin acid.
Plasma hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity after a
single dose of atorvastatin or simvastatin, either alone or in combination with TMC435 will
be also evaluated.
Clinical Details
Official title: A Phase I, 2-Panel, Open-Label Study in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and the HMG-CoA Reductase Inhibitors Atorvastatin and Simvastatin
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Effect of steady-state (constant concentration of medication in the blood) concentrations of TMC435 on the single dose pharmacokinetics (what the body does to the drug) of simvastatin and the active metabolite simvastatin acidEffect of steady-state concentrations of TMC435 on the single dose pharmacokinetics of atorvastatin and the active metabolites ortho- and parahydroxylated atorvastatin Plasma hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity after a single dose of atorvastatin or simvastatin, either alone or in combination with TMC435
Secondary outcome: To evaluate the steady-state pharmacokinetics of TMC435 in the presence of atorvastatin or simvastatinNumber of participants with adverse events as a measure of safety and tolerability
Detailed description:
This is a Phase I, 2-panel, open-label (all people know the identity of the intervention)
study in healthy participants to investigate the pharmacokinetic interaction between TMC435
and the HMG-CoA reductase inhibitors atorvastatin and simvastatin. The study consists of a
screening period (21 days prior to the first intake of study medication), a 17-day treatment
period and a 5-7 days follow-up period. Approximately thirty six healthy participants will
be equally divided to 2 panels (n=18 per panel). Within each panel all participants will
receive the same treatments in the same order. In Panel 1, each participant will be
administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants
will receive TMC435 at a dose of 150 mg once daily from Day 4 until Day 15. In Panel 2, each
participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13.
TMC435 at a dose of 150 mg will be administered once daily from Day 4 until Day 15.
Treatment duration (including Day - 1) will be 17 days for both panels (Panel 1 and Panel 2).
Safety and tolerability will be evaluated throughout the study.
Eligibility
Minimum age: 19 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must be healthy on the basis of physical examination, medical history, vital signs,
clinical laboratory tests, and 12-lead electrocardiogram performed at screening
- If a woman, before entry she must be postmenopausal for at least 2 years, as
confirmed by follicle stimulating hormone test, or surgically sterile (have had a
total hysterectomy or bilateral oophorectomy, tubal ligation/bilateral tubal clips),
not heterosexually active for the duration of the study, or if of childbearing
potential and heterosexually active, agree to use effective methods of birth control
- If a man and heterosexually active with a woman of childbearing potential, he must
agree to use 2 effective methods of birth control and to not donate sperm during the
study and for 3 months after receiving the last dose of study drug
- Have a Body Mass Index (weight in kg divided by the square of height in meters) of
18. 0 to 30. 0 kg/m2
Exclusion Criteria:
- Has a history of liver or renal insufficiency; significant cardiac, vascular,
pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic,
psychiatric, neoplastic, or metabolic disturbances
- Has a positive Human immunodeficiency virus (HIV)-1 or HIV-2 test at screening
- Has a hepatitis A, B or C infection (confirmed by hepatitis A antibody immune
globulin M, hepatitis B surface antigen, or Hepatitis C virus (HCV) antibody,
respectively) at screening
- Pregnant or breastfeeding woman
Locations and Contacts
Lincoln, Nebraska, United States
Additional Information
Starting date: June 2012
Last updated: March 1, 2013
|